News & Videos - NYXOAH

Nyxoah to Participate in the Piper Sandler 36 th Annual Healthcare Conference Mont-Saint-Guibert, Belgium – November 20, 2024, 10:05pm CET / 4:05pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today announced that the Company will participate in the Piper Sandler 36 th Annual Healthcare Conference on Wednesday,...

REGULATED INFORMATION November 19, 2024, 7:00am CET / 1:00am ET NYXOAH SA (Euronext Brussels/Nasdaq: NYXH) Rue Edouard Belin 12, 1435 Mont-Saint-Guibert, Belgium (hereinafter the “ Company ”) Invitation to attend the special shareholders’ meeting of the Company to be held on December 19, 2024 The board of directors of the Company is pleased to invite its securities holders to attend the special shareholders' meeting of the Company, to be held on Thursday , December 19, 2024 at 3:00 p.m....

REGULATED INFORMATION Publication relating to transparency notifications Mont-Saint-Guibert (Belgium), November 18, 2024 , 10:30 pm CET / 4:30 pm ET – In accordance with article 14 of the Act of 2 May 2007 on the disclosure of large shareholdings, Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) announces that it received a transparency notification as detailed below. On November 15, 2024, Nyxoah received a transparency notification from ResMed Inc. following the passive crossing of a threshold....

EQS-News: Nyxoah SA. / Schlagwort(e): Quartalsergebnis Nyxoah gibt Finanzergebnisse für das dritte Quartal 2024 bekannt und informiert über die Unternehmensentwicklung 06.11.2024 / 22:05 CET/CEST Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. Nyxoah gibt Finanzergebnisse für das dritte Quartal 2024 bekannt und informiert über die Unternehmensentwicklung FDA-Zulassung für das erste Quartal 2025 erwartet; US-Vertriebsteam im Aufbau Unternehmen bis Mitte 2026...

EQS-News: Nyxoah SA. / Key word(s): Quarter Results Nyxoah Reports Third Quarter Financial and Operating Results 06.11.2024 / 22:05 CET/CEST The issuer is solely responsible for the content of this announcement. Nyxoah Reports Third Quarter Financial and Operating Results FDA approval on track for first quarter 2025, U.S. commercial team build out in progress Company fully funded with cash until mid 2026 Mont-Saint-Guibert, Belgium – November 6, 2024, 10:05pm CET / 4:05pm ET – Nyxoah SA...

INFORMATIONS RÉGLEMENTÉES N yxoah Présente ses Résultats Financiers et d’Exploitation pour le Troisième Trimestre 2024 L'approbation de la FDA est en bonne voie pour le premier trimestre 2025, l'équipe commerciale américaine est en cours de constitution La Société est entièrement financée par des liquidités jusqu'à la mi-2026 Mont-Saint-Guibert, Belgium – 6 Novembre 2024, 22h05 CET / 16h05 ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (« Nyxoah » ou la « Société »),...

EQS-News: Nyxoah SA. / Schlagwort(e): Konferenz Nyxoah kündigt Teilnahme an der Münchner Kapitalmarkt Konferenz und dem Deutschen Eigenkapitalforum an 05.11.2024 / 10:00 CET/CEST Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. Nyxoah kündigt Teilnahme an der Münchner Kapitalmarkt Konferenz und dem Deutschen Eigenkapitalforum an Mont-Saint-Guibert, Belgien – 05. November 2024, 10:00 Uhr MEZ – Nyxoah SA (Euronext Brüssel/Nasdaq: NYXH) („Nyxoah“ oder das...

Nyxoah Appoints John Landry as Chief Financial Officer Current CFO, Loïc Moreau, to Transition into Role of President International Mont-Saint-Guibert, Belgium – November 4, 2024, 10:45pm CET / 4:45pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today announced the appointment of John Landry as Chief Financial...

REGULATED INFORMATION Publication relating to transparency notifications Mont-Saint-Guibert (Belgium), October 25, 2024 , 10:30 pm CET / 4:30 pm ET – In accordance with article 14 of the Act of 2 May 2007 on the disclosure of large shareholdings, Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) announces that it received a transparency notification as detailed below. Vestal Point Capital On October 23, 2024, Nyxoah received a transparency notification from Vestal Point Capital following an...

Nyxoah to Release Third Quarter 2024 Financial Results on November 6, 2024 Mont-Saint-Guibert, Belgium – October 22, 2024, 10:30pm CET / 4:30pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that the Company will release financial results for the third quarter 2024 on Wednesday, November 6, 2024,...

INFORMATION RÉGLEMENTÉE Publication relative à des notifications de transparence Mont-Saint-Guibert (Belgique), le 15 octobre 2024 , 22:30h CET / 16:30h ET – Conformément à l'article 14 de la loi du 2 mai 2007 relative à la publicité des participations importantes, Nyxoah SA (Euronext Brussels/Nasdaq : NYXH) annonce qu’elle a reçu trois notifications de transparence comme détaillées ci-dessous. Jürgen Hambrecht Le 15 octobre 2024, Nyxoah a reçu une notification de transparence de...

INFORMATION RÉGLEMENTÉE Informations sur le nombre total de droits de vote et d'actions Mont-Saint-Guibert (Belgique), le 9 octobre 2024, 22:35h CET / 16:35h ET – Conformément à l'article 15 de la loi du 2 mai 2007 relative à la publicité des participations importantes, Nyxoah SA (Euronext Brussels and Nasdaq: NYXH) publie les informations ci-dessous suite à l'émission de nouvelles actions. Capital: EUR 6.423.111,21 Nombre total de titres avec droits de vote: 37.389.015 (tous des...

REGULATED INFORMATION Publication relating to transparency notifications Mont-Saint-Guibert (Belgium), October 9, 2024 , 10:30 pm CET / 4:30 pm ET – In accordance with article 14 of the Act of 2 May 2007 on the disclosure of large shareholdings, Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) announces that it received a transparency notification as detailed below. BlackRock, Inc. On October 7, 2024, Nyxoah received a transparency notification from BlackRock, Inc. and related persons following a...

EQS-News: Nyxoah SA. / Key word(s): Financing Nyxoah Raises $27 Million through its At-the-Market Offering 08.10.2024 / 14:00 CET/CEST The issuer is solely responsible for the content of this announcement. Nyxoah Raises $27 Million through its At-the-Market Offering Investment by a new U.S.-based healthcare investor, strengthening the balance sheet and reinforcing U.S. focus Mont-Saint-Guibert, Belgium – October 8, 2024 – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the...

EQS-News: Nyxoah SA. / Schlagwort(e): Finanzierung Nyxoah sichert sich 27 Millionen US-Dollar durch ein Angebot von Aktien zum Marktpreis 08.10.2024 / 14:00 CET/CEST Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. Nyxoah sichert sich 27 Millionen US-Dollar durch ein Angebot von Aktien zum Marktpreis Investition eines neuen US-amerikanischen Investors mit Fokus auf den Gesundheitssektor, Stärkung der Liquidität und des US-Fokus Mont-Saint-Guibert, Belgien – 08....

INSIDE INFORMATION REGULATED INFORMATION Nyxoah Raises $27 Million through its At-the-Market Offering Investment by a new U.S.-based healthcare investor, strengthening the balance sheet and reinforcing U.S. focus Mont-Saint-Guibert, Belgium – October 7, 2024, 11:00pm CET / 5:00pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through...

EQS-News: Nyxoah SA. / Key word(s): Study results DREAM Pivotal Study Data Presented at the International Surgical Sleep Society 2024 Educational Update 27.09.2024 / 22:30 CET/CEST The issuer is solely responsible for the content of this announcement. DREAM Pivotal Study Data Presented at the International Surgical Sleep Society 2024 Educational Update Additional clinical data on patients suffering from Obstructive Sleep Apnea (OSA) demonstrate a clinically significant 71.0% median reduction in...

EQS-News: Nyxoah SA. / Schlagwort(e): Studienergebnisse Nyxoah präsentiert Ergebnisse aus der pivotalen DREAM-Studie auf dem Educational Update 2024 der International Surgical Sleep Society 27.09.2024 / 22:30 CET/CEST Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. Nyxoah präsentiert Ergebnisse aus der pivotalen DREAM-Studie auf dem Educational Update 2024 der International Surgical Sleep Society Zusätzliche klinische Daten von Patienten mit obstruktiver...

Les Données de l'Étude Pivot DREAM Présentées lors de l'International Surgical Sleep Society 2024 Educational Update Des données cliniques supplémentaires sur des patients souffrant d'apnée obstructive du sommeil (AOS) démontrent une réduction médiane cliniquement significative de 71,0 % de l'indice d'apnée-hypopnée (IAH) en position couchée sur le dos à 12 mois par rapport à la valeur de référence. 82,0 % des patients ayant passé une polysomnographie à 12 mois avaient un IAH...

REGULATED INFORMATION Information on the total number of voting rights and shares Mont-Saint-Guibert (Belgium), September 27, 2024 , 08:05 am CET / 2:05 am ET – In accordance with article 15 of the Law of 2 May 2007 on the disclosure of large shareholdings, Nyxoah SA (Euronext Brussels and Nasdaq: NYXH) publishes the below information following the issue of new shares. Share capital: EUR 5,907,711.21 Total number of securities carrying voting rights: 34,389,015 (all ordinary shares) Total...